The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.

Both lobeline and lobelane attenuate methamphetamine self-administration in rats by decreasing methamphetamine-induced dopamine release via interaction with vesicular monoamine transporter-2 (VMAT2). A novel derivative of nor-lobelane, cis-2,5-di(2-phenethyl)-pyrrolidine hydrochloride (UKCP-110), and its transisomers, (2R, 5R)-trans-di-(2-phenethyl)-pyrrolidine hydrochloride (UKCP-111) and (2S, 5S)-trans-di-(2-phenethyl)-pyrrolidine hydrochloride (UKCP-112), were evaluated for inhibition of [H-3] dihydrotetrabenazine binding and [H-3] dopamine uptake by using a rat synaptic vesicle preparation to assess VMAT2 interaction. Compounds were evaluated for inhibition of [H-3] nicotine and [H-3] methyllycaconitine binding to assess interaction with the major nicotinic receptor subtypes. In addition, compounds were evaluated for inhibition of methamphetamine-evoked endogenous dopamine release by using striatal slices. The most promising compound, UKCP-110, was evaluated for its ability to decrease methamphetamine self-administration and methamphetamine discriminative stimulus cues and for its effect on food-maintained operant responding. UKCP-110, UKCP-111, and UKCP-112 inhibited [H-3] dihydrotetrabenazine binding (K-i = 2.66 +/- 0.37, 1.05 +/- 0.10, and 3.80 +/- 0.31 mu M, respectively) and had high potency inhibiting [H-3] dopamine uptake (K-i = 0.028 +/- 0.001, 0.046 +/- 0.008, 0.043 +/- 0.004 mu M, respectively), but lacked affinity at nicotinic receptors. Although the trans-isomers did not alter methamphetamine- evoked dopamine release, UKCP-110 inhibited (IC50 = 1.8 +/- 0.2 mu M; I-max = 67.18 +/- 6.11 mu M) methamphetamine- evoked dopamine release. At high concentrations, UKCP-110 also increased extracellular dihydroxyphenylacetic acid. It is noteworthy that UKCP-110 decreased the number of methamphetamine self-infusions, while having no effect on food-reinforced behavior or the methamphetamine stimulus cue. Thus, UKCP-110 represents a new lead in the development of novel pharmacotherapies for the treatment of methamphetamine abuse.